At OncoHost, our mission is to transform the approach to precision medicine and improve patient outcomes.
Ofer Sharon, M.D.
Ofer Sharon, M.D., is a physician and entrepreneur with over 20 years of experience in clinical research, pharma, and biotech, and has made vital contributions to the acceleration of personalized medicine and oncology drug development.
Chris Dingman is a top-performing and proven sales leader with expertise in oncology molecular diagnostics and the pharma industry.
As we navigate the challenging landscape of the current Israel-Gaza war, the collaboration between our Israeli and U.S. teams has proven invaluable. Our scientific and commercial results serve as a testament to the strength and expertise that arise when these two nations work together toward a common goal.
We developed the PROphet® platform to solve vital clinical questions faced by providers and patients alike. Combining bioinformatics, system biology, proteomic pattern recognition, and machine learning, PROphet® predicts a patient’s probability of clinical benefit in response to some of the most commonly used immunotherapies.
While these treatment modalities have played a major role in revolutionizing cancer therapy, there is still a clear lack of robust biomarkers for guiding treatment decisions for patients being treated with them. Starting with non-small cell lung cancer, PROphet® is providing a solution to this long-standing issue.
We recently announced the analytical validity of PROphet® as a decision-support tool for metastatic non-small cell lung cancer (NSCLC) patients, demonstrating strong experimental precision and accuracy performance, as well as strong computational accuracy. Predictive tools that combine proteomics-based analysis with a computational model are rare, and this breakthrough represents a unique approach, highlighting our team’s innovative work and effort to set a high standard in this field.
In addition, we have a newly developed predictive biomarker for significant immune-related adverse events (irAEs) in patients with NSCLC. This milestone directly addresses a crucial challenge in cancer treatment. While immunotherapy has shown success in treating NSCLC, immune-related adverse events pose a complex challenge, complicating and affecting treatment efficacy and patients’ quality of life. The ability to anticipate the risk of irAEs in these patients prior to commencing treatment is a game-changer, as it enables the development of personalized management plans and strategies for risk reduction.
These achievements are not only a testament to our innovation, but a shining example of our determination to make a lasting impact. It brings us great pride to witness the growth of our company and the vast pipeline of indications that are coming to fruition through our PROphet® platform.
Working harder in challenging times
The current circumstances have tested the strength and resilience of individuals, communities, and businesses. Amidst these challenges, we are proud to stand as a testament to the unyielding spirit of unity between the United States and Israel in the precision oncology field. The synergy between our two teams, with their shared strength, knowledge, and expertise, is the driving force behind OncoHost’s continued commercial success and the increasing adoption of our PROphet® NSCLC test.
The bottom line is simple: We work harder now than ever.
While war rages on, our Israel and U.S. teams develop, innovate, educate, and collaborate. This is an example of all the good that comes from our two countries working together.
In these trying times, the connection between Israel and the United States stands as a beacon of hope and serves as a reminder that even in times of hardship, the quest for improved patient outcomes knows no bounds. Our dedication isn’t merely a business decision — it’s a moral commitment to improving patients’ lives and standing firm against the forces of terror.
Together, we are reshaping the future of healthcare, one breakthrough at a time.